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ABSTRACT 
Pharmacokinetics involves the analysis of plasma concentration and time data to obtain 
models that summarize the absorption, distribution and elimination parameters of a 
drug. The population approach to pharmacokinetics involves the estimation of mean 
pharmacokinetic parameters and their variability within the population. 
Cyclosporine is a widely used immunosuppressive agent, and its pharmacokinetic 
parameters are characterized by a large variation in blood concentrations after oral or 
intravenous administration. Cyclosporine being a narrow therapeutic index drug is 
associated with significant consequences if the drug is present in 'sub-therapeutic' or 
'supra-therapeutic' concentration. Optimization of therapy is challenging owing to 
variable pharmacokinetic parameters and narrow therapeutic index. 
Population pharmacokinetic approach is used in this study to identify and characterize 
demographic and pharmacological variables that influence the pharmacokinetics of 
cyclosporine in lung transplant recipients. 
Cyclosporine concentration-time data obtained through a randomized, prospective 
clinical trial was re-analyzed. A total of 1004 abbreviated cyclosporine profiles were 
available from 48 patients at 1, 2, 3, 4, 12, 24, 36 and 52 post operative weeks. 
Population modeling was performed using NONMEM (Version V). A one-
compartment model with first-order absorption and elimination was used to model the 
data. Exponential models were used for inter-individual variation on oral clearance 
(CUF) and volume of distribution (V!F). A proportional model was used for 
residual error. 
Estimates of CUF and V!F (±S.E) were 26.4 (3 .7) Uh and 183 (37) L, 
respectively. Concomitant itraconazole and diagnosis of cystic fibrosis were 
identified as significant covariates for CUF. Time post transplant and different 
formulations were significant when modeled on bioavailability. With this model 
the estimated coefficients of variation were 18.5% and 49.6% for interpatient 
variability in CUF and residual variability, respectively. Patients taking 
itraconazole were found to have a CUF of 11.6 (4.3) Uh, 43.9% that of the other 
patients. Patients with cystic fibrosis had CUF of 52.3 (6.9) Uh, 50% higher 
than patients without cystic fibrosis . Relative bioavailability of cyclosporine 
from Sandimmune® was 87% that of Neoral®. 
In conclusion, the covariates which influenced the pharmacokinetics of study 
population were concomitant itraconazole, diagnosis of cystic fibrosis, time post 
transplant and different formulation. 
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PREFACE 
This document was prepared in the format of manuscript plan in accordance to the 
Graduate School guidelines of the University of Rhode Island. The thesis is divided 
into two sections. 
Section I is composed of two manuscripts. Manuscript I is a general introduction to the 
topic of research, encompassing the introduction to pharmacokinetics, population 
pharmacokinetics, cyclosporine and cystic fibrosis. Manuscript II consists of the main 
body of this thesis, written in a format required for scientific journal submission. 
Section II contains appendix that includes additional information and details of control 
file useful in the analysis to understand the work in Section I. A bibliography follows 
section II in which all sources used as references in this document are cited. 
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( MANUSCRIPT I 
INTRODUCTION 
Pharmacokinetics is the study of the relationship between the dose of a drug 
and the manner in which its plasma concentrations change over time. More 
specifically, pharmacokinetics involves the analysis of plasma concentration 
and time data to obtain models that summarize the dose-plasma concentration 
relationship in terms of the absorption, distribution and elimination parameters 
of a drug. An understanding of drug's pharmacokinetic characteristics is 
important for drug development and the determination of safe and effective 
doses. Pharmacokinetic studies can also be used to investigate the effects of 
demographical characteristics such as weight, disease status, sex, age etc that 
may influence the dose-plasma concentration profile (1). 
There are broadly two ways of determining a drug's pharmacokinetic 
characteristics in a population. Firstly, the traditional analysis which involves 
modeling each individual's concentration-time data to obtain individual 
pharmacokinetic parameters. Individual parameters are then averaged to 
determine the population values. Secondly pharmacokinetic analysis can also 
be conducted using a population approach in which the pharmacokinetic 
parameters of the population are determined directly. 
1 
( The traditional approach to pharmacokinetic studies involves taking intensive 
plasma samples, up to 10-20 per individual, from a small group of subjects or 
patients. The data from each subject are individually fitted to a 
pharmacokinetic model (e.g., a one- or two- compartment model) to obtain the 
individual's pharmacokinetic parameters. Then summary statistics such as the 
mean and the variance of the group are calculated by pooling each individual's 
pharmacokinetic parameters. Limitations to the traditional approach are that 
only a small number of individuals can be studied and the subjects tend to be 
either healthy volunteers or relatively healthy patients with only a mild form of 
the disease. Thus the population is generally not representative of the true 
population to be treated (2). 
In contrast to the traditional approach, the population approach to 
pharmacokinetic modeling often uses sparse data i.e. only a few samples from 
each subject. The sparse sampling is balanced with study of a large and often 
diverse study population. The population approach also provides estimates of 
the inter-individual variability of the pharmacokinetic parameters in the 
population. Sources of inter-individual variability such as patient age, weight, 
sex, disease condition, and concomitant medications can be identified and their 
relationship to the pharmacokinetic parameters quantified. Identification of 
these factors and the modeling of their relationship to the specific 
pharmacokinetic parameters is an important component of the population 
2 
approach and is valuable in allowing more rational dosage regimens in patients 
(3). Also the population approach provides estimates of residual or intra-
individual error due to random error and model mis-specification. Thus 
population approaches is particularly useful for the study of intra- and inter-
individual variability. 
In summary, the population approach to pharmacokinetic analysis is performed 
to (i) estimate the mean pharmacokinetic (PK) parameters in a patient 
population, (ii) investigate and identify patient characteristics as sources of 
variability (covariates) which influence the PK of drug, (iii) estimate the 
unexplainable interindividual variability, and (iv) estimate the random residual 
variability (including intraindividual, measurement error) . 
Population Approach 
There are two components to a population pharmacokinetic model. The first 
part is the structural model, which characterizes the specific pharmacokinetic 
model and the relationship of the pharmacokinetic parameters to the patient 
characteristics. The second part is the statistical model, which quantifies 
unexplainable variability of the data (4). 
3 
( 
( 
The population model will be explained using a simple example using one-
compartment model for IV bolus input: 
Cpj = D e -CL tj 
v v 
(Eq.1) 
Where Cpj is the observation at time j, as a function of dose (D), volume of 
distribution (V), time (t) and clearance (CL). Note CUV = k. It is recognized 
that the value of each parameter will vary in a population. 
Various models can be used to describe parameter variability. The simplest 
model is for additive error: 
C~ = CLpop + Tl (Eq.2) 
Where C~ is the CL in individual 'i' and CLp0 p is the population mean. The 
parameter eta (T}) represents difference between CLi and CLpop· Every 
individual in the population has a specific value for their pharmacokinetic 
parameter, which will differ from the population typical value due to 
unexplainable variability, which is quantified by using the parameter eta (rt). It 
is assumed that rt is normally distributed with a mean of zero and Standard 
deviation of w. Similar models can be used for V. 
4 
Additional models can be used to explain the difference between the predicted 
and measured concentration in an individual. The difference between the 
predicted and measured concentrations is due to residual or intra-individual 
variability. Again the simplest model for this type of variability is an additive 
model, which has the form: 
Cpi,j = Cpmij + c (Eq. 3) 
Where E (Epsilon) represents the difference between the model predicted 
concentration (Cpmij) in individual i at time j and the actual plasma 
concentration (Cpij) in individual i at time j. Again Eis assumed to be normally 
distributed with a mean of zero and a standard deviation of cr. 
Non-linear Mixed Effect Modeling (NONMEM) 
The principle objective of modeling pharmacokinetic data is to find parameter 
values that reduce the difference between the observed data and predicted data 
(5). The relationship between concentration-time is non-linear; hence non-
linear modeling techniques are required to fit a line through the data to obtain 
parameter estimates. A number of computer software packages have been 
developed for population analysis and Non-linear Mixed Effect Modeling 
(NONMEM) developed by Beal and Shiener (6) is most commonly used 
5 
software in population studies. It uses a true population approach in that the 
population parameters are determined in a single stage of analysis (7). 
The term tnixed effects modeling is used to describe the modeling process 
since two types of parameters ("effects") are estimated. The fixed effect 
parameters are associated with the pharrnacokinetic model and the random 
effect parameters describe the inter- and intra- individual variability associated 
with the statistical model (8). The fixed effects are represented by the 
population pharrnacokinetic parameters and covariates relating them to patient 
characteristics. Thus, fixed effects include the dose, clearance (CL) and 
volume of distribution (V), and coefficients linking physiological factors such 
as age, weight and creatinine clearance and other factors such as concomitant 
medications to the pharrnacokinetic parameters (3) (8). In NONMEM the fixed 
effect parameters are usually given the symbol theta. 
Random-effect parameters quantify variability in the model arising from 
interindividual (between subjects) and intra-individual (within subjects) 
variation (3). Interindividual variability is the seemingly random between 
subject variability in the pharmacokinetic parameters that cannot be explained 
in terms of fixed effects. It is important to obtain an estimate of unexplained 
variability for a new drug because of the safety and efficacy of a drug tends to 
decrease as the unexplained variability in its pharrnacokinetic parameters 
6 
( increases (4). Intra-individual or residual variability is the unexplainable 
variability that occurs at the level of an observed plasma concentration. It may 
arise from the measurement error, model misspecification, and random 
variation in a patient's pharmacokinetic parameters that can occur over time 
(3) (8) (9) (10). 
NONMEM can be used to derive a population model from randomly collected 
sparse data. The data from all individuals are pooled into one data set but 
individuals are still identifiable and this permits different numbers of repeated 
measures for the individuals. Once a population model has been derived a 
Bayesian post-hoc step can be invoked to permit the estimation of the 
pharmacokinetic parameters for each individual in the data set. The ability of 
NONMEM to take advantage of sparse data makes it ideally suited for the 
study of those populations where intensive sampling may be difficult and/or 
unethical, such as the very old, very young or very sick (6). Output from 
NONMEM includes estimates of mean variances and covariances of the 
parameters (6). 
7 
( CY CLOS PO RINE 
A group of compounds called cyclosporines were isolated from the soil as 
major secondary metabolites of the fungus Tolypocladium infatum Garns 
(formerly Trichoderma polysporum). These substances were initially found to 
have antifungal activity. Cyclosporine A (CsA) is one of the major metabolites, 
and it has revolutionized organ transplantation. CsA is a neutral, hydrophobic, 
cyclic peptide containing 11 amino acids, (Fig 1) having a molecular weight of 
1202.1, (C62H 111N 11 0 12). Rather than acting as a cytotoxic agent, which 
defined the activity of a number of available immunosuppressive drugs at that 
time, cyclosporine produces an immunomodulatory effect principally on the 
helper/inducer (CD4) lymphocytes, which orchestrate the generation of 
immune response. 
Mechanism of Action 
The exact mechanism(s) of immunosuppressive action of CsA has not been 
fully elucidated but appears to mainly involve inhibition of lymphocytic 
proliferation and function. It has been suggested that immunosuppressive 
action of cyclosporine results from specific and reversible inhibition of the 
immunocompetent T-cells in the GO (resting) or Gl (post-mitotic, or 
presynthetic) phase of the cell cycle (11). CsA suppresses some humoral 
8 
( immunity but is more effective against T cell-dependent immune mechanism 
such as those underlying transplant rejections and some form of autoimmunity 
(12) . It preferentially inhibits antigen-triggered signal transduction in T 
lymphocytes, blunting expression of many lymphokines, including IL-2, as 
well as expression of antiapoptonic proteins. Cyclosporine forms a complex 
with cyclophilin, a cytoplasmic receptor protein present in the target cell. This 
complex binds to calcineurin, inhibiting Ca++-stimulating dephosphorylation of 
the cytosolic component of NFAT (nuclear factor of activated T-cell) (13). 
When the cytoplasmic component of NFAT is dephosphorylated, it 
translocates to the nucleus, where it complexes with nuclear components 
required for complete T-cell activation, including transactivation of IL-2 and 
other lymphokines genes. Calcineurin enzymatic activity is inhibited following 
physical interaction with the cyclosporine/cyclophilin complex. This results in 
the blockade of NFAT dephosphorylation; thus, the cytoplasmic component of 
NFAT does not enter the nucleus, gene transcription is not activated, and the T 
lymphocyte fails to respond to specific antigenic stimulation. 
9 
( Pharmacokinetics of Cyclosporine 
Absorption and Bioavailability 
CsA is absorbed in the upper part of the GI tract (14). Oral absorption of 
cyclosporine is slow and variable. The extent of absorption depends on the 
individual patient, patient population (e.g., transplant type), post transplant 
time, bile flow, GI state, and the formulation administered. CsA is a lipophilic 
drug and was first marketed in an oil-based formulation, Sandimmune® 
(Novartis Pharmaceutical) in 1983. The absorption of CsA from Sandimmune 
is associated with marked pharmacokinetic variability with large variation in 
the area under the time-blood CsA concentration curve (AUC), Cmax and 
Tmax (15). Emulsification of the crude oil-in-water droplet mixture formed on 
contact with GI fluids by bile salts is necessary before cyclosporine can be 
absorbed. Thus, the absorption is known to be highly dependent on bile 
production and early graft dysfunction with poor bile production and the use of 
external biliary drainage in patients lead to poor cyclosporine absorption (16) 
(17). The poor and highly variable absorption of the drug from Sandimmune 
hindered attainment of adequate cyclosporine concentration in the early post 
operative period (18) (19) and has been shown to be important risk factor of 
both acute and chronic rejection after organ transplant (20). The oral 
bioavailability of Sandimmune varies between 1 and 89%, with a mean value 
10 
( of around 30% (21) (22). As a result of the biliary emulsification step noted 
above, the extent of absorption of Sandimmune can vary according to the 
presence of food, bile flow and GI motility. 
To overcome the problems of poor and variable absorption of cyclosporine 
from Sandimmune, a microemulsion formulation Neoral®, was developed 
(23). This formulation incorporates cyclosporine in a microemulsified 
preconcentrate with a surfactant, lipophilic and hydrophilic solvents, and a 
hydrophilic co-solvent. Using this preparation, cyclosporine is more rapidly 
absorbed from the gastrointestinal tract so that blood concentrations reach a 
higher Cmax within a shorter time than with the Sandimmune (Table 1). It was 
found that following oral administration of Neoral, the time to peak blood 
concentration (Tmax) is 1.5 to 2.0 hours compared to 3.5 hours for 
Sandimmune (23) (25) (24). The dispersion of the microemulsion formulation 
within the intestinal tract does not rely on emulsification with the bile salts; 
hence CsA is absorbed more uniformly from Neoral than from Sandimmune. 
Furthermore, several studies have also documented a significant reduction in 
the incidence of acute cellular rejection in Neoral-treated versus Sandimmune-
treated de nova renal (25) (26) liver,(27) (28) lung, (29) and cardiac (30) 
transplant recipients. Neoral has shown to reduce the variability in the 
gastrointestinal absorption of cyclosporine with an average bioavailability 30% 
higher than that of Sandimmune (17). 
11 
( 
Administration with food both delays and decreases absorption . High- and 
low- fat meals consumed within 30 minutes of administration decreases the 
AUC by approximately 13% and maximum concentration by 33%. This makes 
it imperative to individualize dosage regimes. 
Distribution 
Cyclosporine is distributed extensively outside the vascular compartment. In 
the body, cyclosporine accumulates mainly in fat-rich organs including liver, 
adipose tissue and lymph nodes. After intravenous dosing, the steady- state 
volume of distribution has been reported to be as high as 3 to 5 liters/kg in 
solid organ transplant recipients. The drug is 98 to 99% bound to plasma 
proteins, crosses the placenta, and is distributed into human milk. Of the 90 to 
98% of circulating cyclosporine bound to plasma proteins, 85 to 90% is carried 
on lipoproteins. Distribution of the cyclosporine within the whole blood is 
dose-dependent with 33 to 47% of the cyclosporine being present in plasma, 4 
to 9 % in lymphocytes, 4 to 12% in granulocytes and 41 to 58% in erythrocytes 
(11). The distribution of cyclosporine in blood is highly temperature 
dependent. It has been reported (31) that at 37°C, 60% of the blood 
cyclosporine was localized in plasma compared with 46% at room temperature, 
which may be due to high affinity of cyclosporine for plasma protein, 
12 
( including lipoproteins, at elevated temperatures (32). Due to this temperature 
dependency, whole blood is presently the preferred matrix for the therapeutic 
monitoring of total cyclosporine because storing the blood at different 
temperatures does not alter the total concentrations in blood (33). 
Elimination 
In adults with normal renal and hepatic function, the initial elimination half-
life has been reported to be an average 1.2 hours, with a terminal elimination 
half-life of 8 to 27 hours (range 4 to 50 hours) (11). Clearance from the blood 
is approximately 0.3 to 0.4Uhrfkg in adults undergoing renal or hepatic 
transplantation, but is slightly lower after cardiac transplantation. Clearance in 
infants appears to be several times higher than in adults and is approximately 
doubled in older children (11). 
Cyclosporine is extensively metabolized in the liver by the cytochrome-P450 
3A (CYP3A) enzyme system and to a lesser degree in the gastrointestinal tract 
and the kidneys(34). The metabolism of cyclosporine is influenced by liver 
function. Pre-systemic extraction of cyclosporine is extensive after oral 
administration and is a major cause of the low bioavailability of CsA. 
Cyclosporine undergoes restrictive clearance and the pre-systemic extraction 
primarily occurs in the GI mucosa (14). The metabolism of cyclosporine 
13 
( molecule involves mainly hydroxylation, demethylation and cyclisation of 
different amino acids while the cyclic structure remains intact. Major 
metabolic pathways that have been identified include hydroxylation of the Cy-
carbon of two leucine residues, C1..- carbon hydroxylation and cyclic ether 
formation (with double bond oxidation) in the 3-hydroxy-N, 4-dimethyl-L-2-
amino-6-octenoyl group and N-demethylation of the N-methyl leucine residues 
(11). Oxidation of cyclosporine yields the major metabolites AMl, AM4N and 
AM9, which account for approximately 70, 21 and 7.5%, respectively of the 
total AUC of cyclosporine. 
Cyclosporine and its metabolites are excreted principally through the bile into 
the feces, with only approximately 6% being excreted in urine. Only 0.1 % of 
cyclosporine is excreted unchanged in urine (24). Cyclosporine is also excreted 
in human milk. 
Toxicity 
The most important and clinically significant side effect of cyclosporine is 
nephrotoxicity. The other principal adverse reactions to cyclosporine therapy 
are tremor, hirsutism, hypertension, hyperlipidemia, and gum hyperplasia (14). 
Nephrotoxicity is limiting and occurs in the majority of patients. 
Nephrotoxicity is characterized with increased BUN (Blood Urea Nitrogen) 
14 
and serum creatinine concentration, and have been observed in 25-32, 38, and 
38% of patients receiving the drug for kidney, heart, or liver allografts, 
respectively. Elevation of BUN and serum creatinine concentrations resulting 
from cyclosporine therapy appear to be dose related, may be associated with 
high trough concentrations of the drug, and are usually reversible upon 
discontinuation of the drug. Mild cyclosporine-induced nephrotoxicity 
generally occurs within 2-3 months after transplantation (11). 
Mild to moderate hypertension also occurs in about 50% of renal transplant 
recipients who receive cyclosporine and in most cardiac transplant patients 
receiving the drug. Hypertension generally develops within a few weeks after 
initiation of cyclosporine therapy and affects both systolic and diastolic blood 
pressure. Tremors reportedly occur in 12-21, 31, or 55% of the patients with 
kidney, heart, or liver allografts, respectively who receive cyclosporine. 
Seizures (particularly when cyclosporine was used in combination with high-
dose corticosteroids), headaches, paresthesia, flushing, and confusion have 
been reported occasionally in patients receiving cyclosporine. 
Drug Interactions with Cyclosporine 
Cyclosporine is metabolized by CYP3A4 and is a substrate of P-glycoprotein, 
hence drug interactions exist with agents that inhibit these pathways or are 
15 
( cleared by these mechanisms. Drugs that induce cytochrome P-450 activity 
could increase the metabolism of cyclosporine and decrease its concentration 
in blood. Because of a large number of drugs interacting with cyclosporine, 
complete avoidance of drug interactions with cyclosporine is very difficult. 
Drugs that inhibit cytochrome 3A4 and/or P-glycoprotein and are known to 
increase cyclosporine concentrations include: calcium channel blockers 
(veraparnil, diltiazem, nicardipine), azole antifungal (fluconazole, itraconazole, 
ketoconazole), macrolide antibiotics (erythromycin, clarithromycin, 
troleandomycine), antivirals (indinavir, nelfinavir, ritonavir, saquinavir), 
steroids (methylpredisolone, oral contraceptive, androgens), psychotropic 
agents (fluvoxarnine, nefazodone), amiodarone, chloroquine, allopurinol, 
bromocriptine, metoclopramide, cimetidine, grapefruit juice (11)(35). 
Drugs that induce cytochrome 3A4 and/or P-glycoprotien and have been found 
to reduce cyclosporine concentrations include: anti-microbials such as 
nafcillin, rifampin and rifabutin, anticonvulsants (phenytoin, carbamazepine, 
phenobarbital, prirnidone), barbiturates, arninoglutethirnide, troglitazone, 
octreotide, and ticlopidine (35). 
Other agents known to cause interactions with cyclosporine are drugs that 
cause nephrotoxicity when administered alone. These include arninoglycoside 
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antibiotics, vancomycin, cotrimoxazole (trimethoprim- sulfamethoxazole), 
amphotericin B, and anti-inflammatory drugs (diclofenac, naproxen, and other 
non steroidal anti-inflammatory drugs) (35). 
Therapeutic Drug Monitoring of Cyclosporine 
Cyclosporine's variable pharmacokinetics result in wide variation in the blood 
concentrations achieved from a given dose of cyclosporine. Consequently 
dosage optimization is frequently performed using therapeutic drug 
monitoring. Monitoring is necessary to achieve clinical efficacy and while 
avoiding toxicity and maintain good tolerability. 
Various approaches are used to monitor CsA (36). These include: (i) the 
measurement of trough concentrations (CO) (ii) the measurement of the area 
under the blood concentration versus time curve (AUC), (iii) limited sampling 
strategies, (iv) monitoring of concentrations at 2 hours post dose (C2), (v) 
Bayesian forecasting, and (vi) pharmacodynamic monitoring. Trough (CO) 
monitoring is the traditional approach of monitoring and involves measurement 
of a single trough blood concentration of cyclosporine. It is simple to carry out 
and is practical for routine clinical analysis. However CO has been found to be 
a poor indicator of total drug exposure and not an accurate predictor of clinical 
efficacy (37) (38). AUC monitoring is a more precise way to monitor, as it is a 
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direct measurement of the extent of exposure to drug; it appears to predict 
clinical outcomes and allows calculation of oral pharmacokinetic parameters 
(20) (39). However it is impractical for routine clinical use, and is costly and 
inconvenient to both clinician and patients (37) (38). Limited sampling 
strategies represent a clinically feasible way to estimate AUC. A regression 
equation, developed from AUC values in a sample population is used to 
estimate subsequent AUC by sampling only 2-3 CsA concentrations at 
optimum times. This method is limited by the validation and predictive power 
of the equations generated (36). Monitoring of concentrations at 2 hours post 
dose is considered as the most useful tool for monitoring. It closely correlates 
with AUC0-4, the period of maximum intra-individual and inter-individual 
variability, and C-2 monitoring is practical and convenient for clinical setting 
(40) (41). The Bayesian forecasting, involves the calculation of 
pharmacokinetic parameters in a patient by blending the patient specific drug 
concentrations with pharmacokinetic and statistical models that have been 
established for the particular patient population. However population databases 
are not generally available for cyclosporine. Finally pharmacodynamic 
monitoring has also been used and it involves the use of in-vivo markers of 
immunosuppression. However it is not widely used because the assays are 
cumbersome, and because of the difficulty in distinguishing rejection from 
toxicity. 
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Analytical Instrumentation for Monitoring Drug Concentration 
Cyclosporine 1s a narrow therapeutic index drug with variable 
pharmacokinetics. Consequently therapeutic drug monitoring is often 
performed to individualize the dose to ensure optimum immunosuppressive 
activity. Monitoring is done using whole blood because of temperature 
dependency in blood-plasma ratio. The assays available for whole blood and 
their associated therapeutic ranges include monoclonal radioimmunoassay 
(range 75-325µg/L), monoclonal antibody fluorescence polarization 
immunoassay (mFPIA) (range 100-400µg/L), polyclonal antibody 
fluorescence polarization immunoassay (pFPIA)(range 200-800µg/L), enzyme 
multiplied immunoassay technique (EMIT) (range 75-375µg/L) and high 
performance liquid chromatography (HPLC) (range 100-325 µg/L) (35). 
HPLC is used as a reference standard method for monitoring cyclosporine 
concentration against which other analytical methods should be validated. 
CYSTIC FIBROSIS 
A varied amount of references are available in clinical textbooks (42), World 
Wide Web (43) and journal articles (44) (45) concerning the clinical 
physiology of cystic fibrosis. Cystic fibrosis (CF) is an inherited disorder that 
affects the body's epithelial cells. Under normal circumstances, certain types 
19 
( of epithelial cells produce mucus and other watery secretions that coat the 
passageways of the lungs, liver, pancreas, reproductive tract, and intestinal 
tract. However, in cystic fibrosis inherited CF gene abnormalities cause these 
epithelial cells to produce secretions that are much thicker than normal , this 
abnormally thick mucus is due to the faulty transport of sodium and chloride 
within cells lining the organs. 
In the lungs of persons with CF, thickened secretions trap microorganisms and 
encourage repeated lung infections. In pulmonary disease airways obstruction, 
impaired mucociliary clearance, bronchiectasis, and chronic infection are 
characteristic of CF and account for the progressive loss of lung function . This 
is marked by an average decline in FEVl (is the forced expiratory volume in 1 
second and determines the capacity of a person to breathe out in one second, 
trying as hard as possible) of roughly 1.5-4% per year. Therapy is directed at 
airway clearance, treatment of exacerbations, and management of airflow 
obstruction. Lung transplantation is a final option for those patients with severe 
progressive pulmonary disease. 
Cystic fibrosis has a variety of symptoms. The most common are: very salty-
tasting skin; persistent coughing, wheezing or pneumonia; excessive appetite 
but poor weight gain; and bulky stools. The sweat test is the standard 
diagnostic test for cystic fibrosis. This simple and painless test measures the 
amount of salt in the sweat. A high salt level indicates that a person has CF. 
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The treatment of CF depends upon the stage of the disease and which organs 
are involved. Antibiotics are also used to treat lung infections and are 
administered intravenously, orally, and/or medicated vapors, which are 
inhaled, to improve breathing. 
Chronic infection in the airways is present in most patients with CF. The 
clinical course of disease is marked by periods of stability which are 
interrupted by exacerbations characterized by increased sputum production, 
dyspnea, fatigue, weight loss, and decline in FEV 1. Exacerbations most often 
result from bacterial infections. Staphylococcus Aureus and Haemophilus 
Influenza are common pathogens in children. The prevalence of Pseudomonas 
Aeruginosa rises during childhood and adolescence so that 80% of CF patients 
are infected with Pseudomonas by age 18. Aggressive treatment of infection is 
the recommended approach, and in the adult therapy is mainly targeted at 
Pseudomonas. A typical antimicrobial regimen consists of intravenous 
tobramycin and an anti-pseudomonal penicillin or cephalosporin. Antibiotics 
are tailored to the results of each individual's sputum culture. 
Bilateral lung transplantation remains an option for severe progressive 
pulmonary disease. An FEVl of 30 percent predicted, frequent hospitalizations 
and pulmonary hypertension are generally used in the decision to refer for 
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( transplantation. Although transplantation offers the only potential life saving 
therapy, the procedure is not without risks as 5-year survival is just under 50%. 
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Figure 1.1. Chemical Structure of Cyclosporine 
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Table 1.1. Comparative pharmacokinetics of Sandimmune and Neoral 
formulation of cyclosporine 
Neoral Sandimmune 
AUC µg/L.h) 
a. 18.17 13.29 
b. 24.4 16.3 
c. 3525 2556 
Cmax (µg/L) 
a. 4.09 2.60 
b. 6.2 4.7 
c. 721 422 
Tmax (h) 
a. 1.69 2.7 
b. 1.7 4.5 
c. 1.5 2.8 
Crnin (µg/L) 
a. 0.67 0.55 
b. NA NA 
c. 151 121 
Reference: a=Kahan et al (46); b=Keown et al (47); c=Keown et al (25) 
AUC shown are at 12-hour intervals. 
AUC= area under the blood concentration versus time curve for 
cyclosporine; Cmax= maximum blood concentration of cyclosporine; 
Crnin= minimum (trough) blood concentration of cyclosporine; Tmax= 
time to Cmax 
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MANUSCRIPT II 
ABSTRACT 
Cyclosporine (CsA), a potent immunosuppressive agent has markedly 
improved the graft survival rate, but owing to its narrow therapeutic index the 
clinical use of cyclosporine is complicated by large intra- and interindividual 
variabilities in its pharmacokinetics, and consequently it is necessary to 
individualize the dose for each patient. Many factors such as patient age, 
gender, time post transplant, concomitant medication, presence of certain 
disease conditions like cystic fibrosis (CF), ethnic origin and gastrointestinal 
status have been believed to influence cyclosporine pharmacokinetics. The 
population pharmacokinetic analysis is ideally suited to study the variability of 
CsA pharmacokinetics within the patient population. Additionally, 
cyclosporine is available in two formulations: Sandimmune, an oil based 
preparation, and Neoral, a microemulsion formulation, which display different 
pharmacokinetic profiles. 
Non linear mixed effect modeling (NONMEM) was used to perform 
population modeling of CsA on blood samples obtained from 48 thoracic 
transplant patients. Samples were collected at weeks 1, 2, 3, 4, 13, 26, 39 and 
52 post transplant. In general each individual provided 3 blood samples per 
visit at approximately time 0, 2 and 6- hours post dose. For the analysis a one-
compartment model with first order absorption was used to describe the model. 
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The value of absorption rate constant (ka) was fixed due to a limited number of 
blood samples in the absorption period. An exponential error model was used 
to describe inter-individual variability in oral clearance (CUP) and a 
proportional error model was used for residual variability. Itraconazole and 
cystic fibrosis were found to be significant covariates for CUP. The type of 
formulation and time post-transplant were identified as significant covariates 
for bioavailability. The final model estimates for CUP were 26.4(± 3.7) Uh. In 
the presence of itraconazole or cystic fibrosis the estimates of clearance were 
11.6 (± 4.3) Uh and 52.3 (± 6.9) Uh , respectively. The bioavailability of 
Sandimmune was found to be 87% that of Neoral. During the first four weeks 
after transplant, in which a linear model was assumed, bioavailability was 
64.5% that in subsequent weeks. The volume of distribution was 183 (± 37) L. 
The estimates of CV for the final model for interindividual variability on CUP 
were 18.5% and for residual variability 49.6%. 
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INTRODUCTION 
Cyclosporine (CsA) is a potent irnrnunosuppressive agent, widely used to 
prevent graft rejections. Cyclosporine has markedly improved the graft 
survival rate, but owing to its narrow therapeutic index and it highly variable 
pharmacokinetics, a whole blood monitoring of CsA concentrations is 
commonly performed to individualize the dose in patients (1). Cyclosporine 
was initially formulated under the brand name Sandirnmune® as an oil based 
formulation which successfully reduced the incidence of acute rejection in 
transplant patients, but this formulation was associated with high inter- and 
intra- patient variability and poor and variable bioavailability (2)(3), and 
attainment of adequate CsA level was particularly difficult. A microemulsion 
formulation of CsA, Neoral® was developed to circumvent some problems 
· associated with Sandimmune (4). Cyclosporine is more rapidly absorbed from 
Neoral, which has a higher Cmax and shorter Tmax. 
Due to the presence of marked intra- and inter-individual variability in CsA 
pharmacokinetics and the serious consequences of plasma concentrations 
outside the therapeutic range, there is a general consensus that a 
pharmacokinetic approach be used to optimize therapy (1)(5). Traditionally, 
trough levels of CsA are monitored (5). However this parameter does not 
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adequately reflect the overall exposure of the patients to CsA other methods 
have also been proposed. These include the blood concentration two hours 
after dose (C2) and the measurement of area under the concentration-time 
curve (AUC) (5). However, the latter method requires the collection of a series 
of blood samples and is impractical in clinical practice. To overcome this 
disadvantage a Bayesian approach using a limited sampling method in 
conjunction with a population pharmacokinetic model has been proposed (6). 
Many factors are believed to influence cyclosporine pharmacokinetics. 
Cyclosporine has a highly variable absorption, which is dependent on liver 
function, bile flow, time post transplant and gastrointestinal status (3). The 
distribution of CsA is mainly influenced by lipoprotein concentration in 
plasma. However, age, gender and obesity do not appear to be important 
factors for distribution. Metabolism of CsA can be influenced by the use of 
concomitant medication, and other factors such as presence of certain disease 
conditions like cystic fibrosis , and ethnic origin (3). 
Cyclosporine is metabolized primarily by cytochrome P450 3A4 in the liver 
and small intestine. Cyclosporine is also a substrate of p-glycoprotein (which 
acts as a counter-transport pump, actively transporting cyclosporine back to the 
intestinal lumen). Unexpected drug interactions can lead to sub-therapeutic 
dosing in case of enzyme inducers, or drug toxicity with enzyme inhibitors. 
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( Itraconazole appears to inhibit both cytochrome P450 3A4 and p-glycoprotein. 
Back et al (7) conducted an in-vitro study using human liver enzymes to 
examine the ability of antifungal drugs to inhibit the metabolism of CsA. They 
found out that ketoconazole was the most potent inhibitor of CsA; itraconazole 
was the next potent, and fluconazole the least potent inhibitor of cyclosporine 
metabolism. Inhibitory effects of itraconazole have also been demonstrated in-
vivo (7). Concomitant administration with CsA increased whole blood or 
serum concentration of CsA and serum creatinine concentrations. 
Cystic fibrosis (CF) affects the mucus and sweat glands of the body and is 
caused by a defective gene. Thick mucus is formed in the breathing passages in 
the lungs and this predisposes the person to chronic lung infections. Lung 
transplant is the treatment of choice for patients with end stage cystic fibrosis. 
This disease has been found to alter the pharmacokinetics of CsA. These 
patients exhibit poor absorption that may lead to ineffective 
immunosuppression and subsequent graft rejection. Patients with CF usually 
have fat malabsorption due to pancreatic insufficiency and require treatment 
with pancreatic enzyme supplements (8). Despite such therapy, the absorption 
of CsA from Sandimmune, which is a lipophilic immunosuppressive agent, has 
been found to be reduced in CF patients (8). The absorption of CsA from 
microemulsion formulation Neoral appears less affected by CF (9). Cystic 
fibrosis patients undergoing heart and lung transplant require a higher dose of 
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CsA and frequent monitoring of blood level to achieve adequate 
immunosuppression. In a study by Tan et al. (10) the apparent oral clearance of 
CsA was found to be about twice as high in patients with CF than in patients 
without CF. This increase could, however, be caused by the poor 
bioavailability of the drug which has been suggested in patients with CF by 
Cooney et al.(11). Other drugs that have shown elevated clearance when 
patients have CF include theophylline, ciprofloxacin, sulfamethoxazole and 
ibuprofen (11). 
Kahan et al. (12) showed patient's age over 45 years had lower CsA clearance 
and male and female patients were shown to differ significantly in their ability 
to clear and distribute CsA. Ethnic background was found to influence the 
bioavailability of Sandimmune. Lindholm et al., (13) found the bioavailability 
(F) of CsA to be significantly lower in black patients than in white patients 
(mean values of 30.9% ± 12.3% and 39.5% ± 16.5%, respectively; p < 0.001). 
The study found that these racial difference in F may contribute to the poorer 
outcome observed after kidney transplantation in black patients. However in a 
controlled study done on healthy African American and white volunteers by 
Stein et al., (14) no difference in pharmacokinetic parameters were found 
between the ethnic groups for Sandimmune and Neoral. However compared to 
Sandimmune, Neoral resulted in an approximately 60% higher Cmax. a 50% 
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greater AUC, and a 25% lower oral clearance in both African American and 
white subjects. 
An understanding of factors that modify CsA pharmacokinetics, particularly its 
bioavailability and clearance is important in order to better predict the 
optimum dose for a patient. This study describes the application of the 
population approach to pharmacokinetic analysis to the study of the 
pharmacokinetics of CsA in thoracic transplant patients. 
MATERIALS AND METHODS 
Study Design: 
Population pharmacokinetics of CsA were studied using data obtained from a 
previously published study (15). A randomized, open-trial study was 
conducted on heart and lung transplant recipients receiving either Sandimmune 
or Neoral as immunosuppressive therapy during the first year of transplant 
conducted at Papworth Hospital, Cambridge, UK. The Local Ethics Committee 
approved the study and approval from the Institutional Review Board (IRB) at 
The University of Rhode Island was obtained to re-analyze the data. In brief, 
blood samples were collected from 48 patients aged 19 to 66. The group 
consisted of 26 males and 22 females who had undergone either single lung 
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I (18 patients), double lung (9 patients), or both heart and lung (21 patients) 
transplant. Twenty-one patients received Sandirnmune and 27 patients were 
administered Neoral. Patients with cystic fibrosis (CF) were randomly selected 
independently because of unusual pharmacokinetic in CF patients. Patients 
with CF received their daily oral CsA at 8-hour intervals rather than the usual 
12-hour interval. 
Immediately following transplant, patients received intravenous 
methylprednisolone and rabbit antithymocyte globulin induced 
irnmunosuppressive therapy was given to all the patients, followed by 
maintenance triple- therapy with oral cyclosporine, azathioprine, and 
prednisolone. A dose of 50 mg of Sandirnmune or Neoral was administered to 
the patients on the first day of their transplant and increased by 50 mg at each 
12- hourly dose until therapeutic trough levels were achieved. Therapeutic 
goals for the trough levels were 300-400µg/L for months 1 and 2 and 200 to 
300µg/L for months 3 and 12. 
Pharmacokinetic Protocol and Analytical Method 
The data collected over 12 month period was stored in a computer database. 
Patients had blood samples drawn for analysis of CsA concentration during 
clinical follow-up visits at weeks 1, 2, 3, 4, 13, 26, 39 and 52. In general each 
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( individual provided 3 blood samples per visit: at approximately time 0- (Co), at 
2- (C2) and 6- hours (C6) post dose. 
Blood cyclosporine concentrations were monitored by Dade-Behring Emit 
2000 immunoassay (Dade-Behring Diagnostic UK, Ltd.; Milton Keynes, UK). 
Special care was taken to ensure that the trial database only included 
cyclosporine measurements taken under steady state conditions. 
Data Presentation and Pharmacokinetic Analysis 
Clinical, pharmacokinetic, and demographic data including dose of CsA, CsA 
blood concentrations, age, body weight, time post transplant (TPT), type of 
formulations given, concurrent medications and disease condition relevant to 
the population analysis, were extracted from the raw data sets and merged and 
formatted using Microsoft® Excel 2000. The concentration time data were 
tabulated for completeness and consistency of recorded sampling and dosing 
time and prepared along with the relevant demographic data for analysis. 
The pharmacokinetic analyses were performed using NONMEM (version V, 
double precision) (S.L. Beal and L.B. Sheiner, NONMEM users guide, 
NONMEM Project Group, University of San Francisco, San Francisco). 
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( Pharmacokinetic Model 
A one-compartment model with first order absorption was used (ADV AN2 and 
TRANS 2) and was parameterized as the first order absorption rate constant 
(ka), apparent clearance (CIJF) and apparent volume of distribution (V!F). 
Since a limited number of blood samples were collected during the absorption 
phase, the absorption rate constant (ka) could not be estimated and was fixed; 
the fixed values were be taken from previously reported population values 
(16): 1.35h-1 and 0.25h-1 for Neoral and Sandimmune, respectively. The 
relative bioavailability (F) of Sandimmune compared to Neoral was also 
estimated. 
Statistical Model 
Additive, proportional or exponential error models were used in developing the 
population model for interindividual variability in the pharmacokinetic 
parameters of CIJF, V!F and Ka. 
The models were: 
9i = 9' +llai For additive-error model, 
9i = 9' [1 + (llai)] For proportional-error model and 
9i = 9' exp Criai) For exponential-error model 
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/ Where Si is the estimate for a pharmacokinetic parameter in the ith individual, 
8' is the population mean of the pharmacokinetic parameter, and flei represents 
the random variable with zero mean and variance w2 that distinguishes the ith 
individual pharmacokinetic parameter from the population mean value 
predicted by the regression model. 
Both proportional error model and combined additive- and proportional- error 
model were used to model residual variability (including intraindividual 
variability). The equations used are 
Cij = C'ij (1 + Elij) For proportional error 
Cij = C'ij (1 + Elij)+ E2ij For combined proportional- and additive-
error models 
Where Cij is the observed serum concentration of the ith individual at time j, 
C'ij is the predicted serum concentration of ith individual at time j, and Elij and 
E2ij are the component of proportional and additive errors with zero mean and 
variance cr2. 
Data Analysis Strategy 
The pharmacokinetic and statistical models were evaluated to determine the 
basic model that best fit the data. A statistically significant decrease (P<0.05) 
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( m the minimum value of the objective function (as measured by the log 
likelihood difference) was used as the criteria to determine the best model. 
Initially, the population pharmacokinetic analysis was conducted without 
including any covariates in the model (basic model). After a basic model was 
identified, a model building process was employed to examine the influence of 
patient covariates on the estimates of pharmacokinetic parameters. The effects 
of the following patient covariates on CUF and V!F were evaluated: age, 
weight, sex, formulation type (Sandimmune or Neoral), presence of cystic 
fibrosis, type of transplant (single lung, double lung and heart and lung), time 
post-transplant and use of concomitant medication. Age, weight, time post-
transplant were examined as continuous variables. Sex, formulation type, 
presence of cystic fibrosis and use of itraconazole as a concomitant medication 
were examined as categorical variables. 
A decrease in the minimum value of objective function of 3.841 or greater 
following introduction of a single covariate into the model was considered 
statistically significant (P<0.05 with 1 degree of freedom) using the x2 
distribution if the 95% confidence intervals (Cl) for the estimate did not 
include null value. If the change in the objective function was 3.8 or greater 
but the 95% CI for the estimate included the null value, the effect of the 
variable was considered to be of borderline significance and that the covariate 
was not included in the full model. It was assumed that no significant 
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( interaction between covariate factors existed. If there was an interaction 
present for an effect that was not significant alone at the P<0.05 level, then the 
effect would be minor and would not likely to be of clinical significance. Thus, 
covariates effects were introduced individually and no covariate - covariate 
interactions were modeled. For the significant covariates the improvement in 
fit was assessed by the precision of the parameter estimate (standard error of 
the mean and 95% confidence interval) and by the reduction in interpatient and 
residual variability. In addition, scrutiny of the scatter-plots of weighted 
residual (WRES) vs. cyclosporine predicted concentrations (PRED) was 
another indicator of the goodness of fit in each model. 
All significant variables were included in the full model and a backward 
elimination process was then employed to eliminate covariates from the full 
model in order to develop the final model. Backward elimination was 
performed by removal of a covariate from the full model one at a time and 
increase in the objective function of 6.68 or greater (P<0.01 with 1 degree of 
freedom) on removal of a covariate from the full model signified that the 
variable was important, and that covariate was retained in the final model. 
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RESULTS 
All error models (additive, proportional, exponential, and combined additive 
and proportional models) were tested to account interindividual variability in 
the pharrnacokinetic parameters (CUF and V IF) and residual error. An 
exponential model for inter-individual variability in the pharrnacokinetic 
parameters and a proportional error model for residual variability best 
described the error models. A null value for the 95% confidence interval was 
observed for interindividual variability in VIF, and hence the error term was 
deleted in case of VIF for all further data analysis, in accordance with the data 
analysis strategy. 
A scatter plot for observed versus model-predicted cyclosporine concentration 
is shown in Figure 2. The mean parameter estimates (95% CI are in 
parentheses) obtained from the analysis of base model is as follows (Table 4): 
CUF 23.lUhr (± 3.3 Uhr); VIF 202 liters (± 43 liters). The estimates for 
coefficient of variation (CV) for interindividual variability on CUF were 
32.1 % and for residual variability 60.1 %. 
After the base model was completed, the influence of covariates was studied 
on both CUF and V IF individually, and since ka was kept constant, none of the 
covariates were estimated for ka. In the model building process the covariates 
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were added to the base model one by one and those covariates which were 
found to have reduced the value of objective function (used as a measure of 
"goodness of fit") significantly (P<0.05) when tested against the base model 
for both CIJF and V!F were considered to be used in the final model building. 
Age and type of transplant (single lung, double lung, heart and lung) were not 
found to be significant covariates for either CIJF or V!F (Table 2). Weight was 
found to be a significant covariate for CIJF but not V!F. However a null value 
was observed in the 95% confidence interval of CIJF (Table 2). Thus weight 
was not considered for the final model, in accordance with the data analyzing 
strategy. 
Time post transplant (TPT) in weeks as a continuous covariate was not found 
to be statistically significant on CIJF. Analysis of the graph of the post-hoc 
values of CIJF versus time post transplant revealed a pattern which suggested 
decrease in CIJF over the first four weeks. Hence, time post transplant was 
modeled as a covariate for the first four weeks according to the formula Fl = 
1- Theta (5)/ TPT as shown in appendix. Modeled in this way time post 
transplant was found to be a significant covariate (Table 2). Estimate of the 
covariate for TPT on F for the first four occasions was 0.509!TPT (±0.076), 
hence TPT was used in the final model building process. 
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In the analysis of the potential influence of gender on CUF and V/F, male 
patients were assigned "1" and females "O". Gender was added as a covariate 
according to the formula TVCL= Theta (1) + Theta (5)*Sex. No significant 
change was observed in objective function when gender was modeled for V/F. 
The change in objective function (160.88) was significant (p<0.05) on CLIP 
and was used for the final model building process. The estimate of CLIP for 
gender was 28.6Uh for male and for females 18.3 Uh (±5.2) (Table 2). 
ltraconazole was modeled as a categorical variable. A value of "O" was 
assigned to patients not taking itraconazole and "1" to patients taking 
itraconazole. On the assumption that itraconazole would reduce the CLIP of 
CsA, itraconazole was modeled as a negative function according to the 
formula: TVCL= Theta (1) - Theta (5)*1tra. Concomitant itraconazole was 
found to be a significant covariate for CLIP (Table 2). The estimates for CLIP 
obtained for patients with itraconazole in their therapy are 11.7 Uh and 
without itraconazole the estimates for CLIP were 28.0Uh, a decrease in CLIP 
by 58.2% (Fig 5). The estimates for coefficient of variation obtained for 
interindividual variability on CL was 31 % (Table 2) and residual variability 
51.7%. ltraconazole was also studied on V/F and no significant difference in 
objective function was seen and hence not considered to be used in the final 
model for V/F. 
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Cystic fibrosis was evaluated by assigning patients with CF as 1 and patients 
without CF as 0. Cystic fibrosis was found to be a significant covariate for 
CLJF (Table 2). The estimates for CLJF when patients have CF and when they 
do not have CF are 54.4 Uh and 21.7 Uh respectively; evident that presence of 
CF increase the value of CLJF by 60% when compared to patients without CF. 
The coefficient of variability for interindividual error on CLJF was 23.7% 
(Table 2) and residual variability 60.6%. Cystic fibrosis was also analyzed on 
V/F, but no change in objective function was observed, hence not considered 
for final model. It was not possible to obtain estimates for cystic fibrosis when 
studied as a covariate on bioavailability (F), but when the different 
formulations (Sandimmune and Neoral) were included in the model, CF was 
found to be a significant covariate for F of Sandimmune and Neoral. However, 
when CF was included as a covariate for CLJF rather than F (on Sandimmune 
and Neoral), a more significant result was obtained. The use of CF as a 
covariate for CUF resulted in a more significant effect (Table 2) than when it 
was used as a covariate for F (on Sandimmune and Neoral). It was found that 
CLJF accounted for a significant change in objective function by 265.80 from 
the base model; however modeling of CF on F (on Sandimmune and Neoral) 
was not used in the final model along with CF on CLJF as it was assumed that 
F would nullify the effect as we had modeled CF on CLJF previously and it 
was found more significant. It was not possible to model CF on both CLJF and 
Fin the model. However just for the records when the analysis using CF on F 
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for both Sandirnrnune and Neoral was done, along with CF on CIJF a null 
value was obtained in the estimates of 95% CI for both Sandirnrnune and 
Neoral, which further confirmed our assumption of not using CF on CUF and 
F together. Thus in the final model CF was used as a covariate for CUF. 
Formulation (Neoral or Sandirnrnune) type was found to be a significant 
covariate for F. Formulation type was also modeled using categorical 
variables; Neoral was assigned a variable "O" and Sandirnrnune "l". The 
model had the form Fl= 1 *Dose+ Theta (5)*(1-Dose). The estimate of Theta 
(5) were 1.39 (±0.45) which showed that the bioavailability of Sandimmune is 
72% that of Neoral. The estimate of interindividual variability for CIJF was 
30% (Table 2) and residual variability 62.4%. 
To summarize, the following were identified as significant covariates for CIJF 
body weight, gender, cystic fibrosis as disease condition, itraconazole as 
concomitant medication, type of formulation (Sandimmune or Neoral), and 
time post transplant (Table 2). The covariates which were not significant were 
age and type of transplant (single lung, double lung or heart and double lung). 
Weight had a null value in the estimate and was not included for final model 
building, inspite of a significant change in objective function. Significant 
covariates were only found for when analyzed for clearance (CIJF), no 
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significant change was observed in the value of objective function when 
covariates were analyzed for volume of distribution (V/F). 
Consideration of the above significant covariates during model building also 
resulted in improvement in the relationship between observed and model-
predicted concentration and weighted residuals versus model-predicted 
concentrations. A reduction in the percentage value of residual random error 
when compared to the base model also indicated a better model fit (Table 2). A 
plot of observed and model-predicted concentration and weighted residual 
versus model predicted for the base model is shown in Figure 2 (a) and (b) 
respectively. 
A full model was then developed containing all the significant covariates. 
Backward elimination was then performed to identify the covariates for the 
final model. The criteria for significance was a measure of change in objective 
function value greater than 6.6 (p<0.01, with one degree of freedom) when a 
covariate was removed from the model. As a result of this process gender was 
eliminated from the model. The covariates CF, itraconazole, time post 
transplant and use of different formulation were retained and added to the final 
model (Table 3). The final model estimates for CUF were 26.4(±3.7), when 
itraconazole was in therapy the estimates were 11.6 Uh (±4.3) and when 
patients had cystic fibrosis 52.3 Uh (±6.9), as per the final model analysis. 
49 
( This showed a decrease in CUF by 58% when patients were on itraconazole 
without CF, an increase of 51 % when patients had CF and no itraconazole in 
therapy and an increase of 32% when patients had CF and were on 
itraconazole. For the final model the estimates for different formulation of 
Sandimmune and Neoral obtained were 1.14 (±0.18), showing bioavailability 
of Sandimmune 87% that of Neoral, similarly the estimates for TPT for the 
first four weeks were 0.355 (±0.107). The estimates of CV for interindividual 
variability on CUF were 18.5% and residual variability 49.6% (Table 3). The 
final model resulted in a better correlation of predicted versus the observed 
concentration when compared with the base model, also a better correlation 
was seen on scrutiny of weighted residual versus predicted concentration for 
final model when compared with the base model (Figure 6a. and 6b.). 
DISCUSSION 
The objective of the study was to estimate apparent clearance (CUF) and 
apparent volume of distribution (V/F) of CsA in patients who have undergone 
heart lung transplantation and to identify patient's characteristics that 
influenced these pharmacokinetic parameters. This would permit more rational 
dosing of CsA and would assist physicians develop initial dosing regimens in 
patients who have characteristics known to influence CsA pharmacokinetics. 
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( A one-compartment model best described the data. Others have found that CsA 
pharmacokinetics are best described by a two-compartment (17). It is likely 
that the limited number of blood samples especially during the distribution 
phase made it impossible to fit the data to a two-compartment model. 
The estimates of CUF and V/F obtained for the base model were 23.1 Uhr (± 
3.3 Uhr) and 202 liters (± 43 liters) respectively, which is in good correlation 
with literature values of 28.lUh and 280L for oral clearance and volume of 
distribution respectively (18). It was not possible to include a term for the 
inter-individual variability of V/F. This is probably because of the paucity of 
informative data during the initial period following the dose. Consequently, the 
inter-individual variability in V IF could not be studied. 
Gender has been found to influence the CYP3A4 activity. Hunt et al (19) 
found the hepatic CYP3A4 activity to be 24% higher in females than males. 
Furthermore, when considered alone gender was found to be significant, 
ultimately gender was not found to be significant in this study where 54% 
patient were male. 
Time post transplant is thought to affect bioavailability rather than apparent 
clearance. In a study by Parke and Charles (20) postoperative day was modeled 
on clearance, but was not found to be statistically significant, but when 
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( modeled on F, a superior fit to the data was obtained with use of mathematical 
formulae. In this study also time post transplant was found to be significant 
when it was modeled on F. On plotting a graph (Fig.I) between normalized 
clearance (clearance in first week divided by clearance in following weeks) 
and time post transplant it was observed that CUF decreased in the first four 
weeks and then stabilize over time, hence it was modeled for the first four 
weeks post transplant. However to be sure, runs were performed in which 
CIJF was allowed to decrease over periods of 3 and 12 weeks; however the 
best results were observed when the CUF was allowed to decrease over a 4 
week period. A mathematical formula was derived which accounted for the 
first four occasions. Estimates obtained were in agreement with previous 
studies that states that the bioavailability of CsA decreases in the 2-3 weeks 
after transplantation and then stabilize (14) (21). 
Comparisons of Neoral pharmacokinetics to Sandimmune formulation have 
been well documented (22) (23). Studies have shown Neoral to be a better 
predictor of exposure and associated with reduced variability when compared 
to Sandimmune. In the previously published study (14) conducted on the same 
patients as this study, Neoral was associated with a higher and more consistent 
exposure compared to Sandimmune. The lower bioavailability of Sandimmune 
is in agreement with other studies, although the relative bioavailability of 
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( Sandimmune (0.87) compared to Neoral is somewhat larger than that published 
in other studies (17) (22) (24). 
Cyclosporine absorption and consequently blood concentration may vary 
significantly according to bile flow, co-administration with food, GI tract 
motility, renal function, and several drugs that patients may receive after 
transplantation (25). Several of these factors are particularly important to 
patients with CF. In CF, hepatobiliary involvement and alterations in bile flow 
are common, and can change in severity in any individual (26). Bile acid is 
required for micellar solubilization with Sandimmune, whereas Neoral is a 
microemulsion that avoids bile salt dependence. In this study, presence of CF 
as a disease condition increased CUF when compared to non-CF patients. This 
observation has also been found by others (27). Patients with cystic fibrosis 
undergoing lung transplant have been found to absorb Sandimmune 
cyclosporine poorly (7). Neoral however has shown to provide better 
absorption and produce higher drug exposure in both heart and lung transplant 
recipients when compared to Sandimmune (8) (28). In this study eight patients 
had cystic fibrosis of which 3 patients took Sandimmune and 5 patients took 
Neoral. It was observed that in the CF patients Sandimmune showed a larger 
CUF than Neoral (Fig. 3). This is probably the result of a lower F in patients 
taking Sandimmune. In a study on CF patients by Reynaud-Gaubert et al, they 
demonstrated a higher and more reliable bioavailability with less intrapatient 
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( variability from Neoral when compared to Sandimmune (27). In the present 
study no definite results could be obtained for the change in bioavailability in 
patients with CF on Sandimmune or Neoral. The relationship of different 
formulations (Neoral and Sandimmune) on CF and non-CF patients was 
initially performed. The estimates obtained for CF when patients were on 
Neoral was 0.52, and 0.193 when on Sandimmune. Similarly the estimates for 
non-CF patients for Neoral and Sandimmune were 1.85 and 0.193 respectively. 
However, when this model was added for final model building, a null value 
obtained, further analysis was not performed as no significant and reliable 
results could be obtained from the comparison. 
The potential for significant drug interactions is well recognized for CsA (3) 
(16) (29) because it is a substrate for cytochrome P-450 3A4 and P-
glycoprotein (30). ltraconazole is a CYP P-450 inhibitor has been shown in 
previous studies (31) (32) to influence cyclosporine pharmacokinetics by 
decreasing clearance. This was confirmed in the present study. The population 
approach to the analysis of pharmacokinetic data is useful for identifying and 
quantifying clinical significant drug interactions without the need for 
controlled clinical investigation (33) (34). Using the population approach it is 
possible to assess the clinical importance of drug interactions in patients 
administered drugs as part of clinical therapy. However it is difficult to 
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( interpret information that suggests a lack of interaction because of problems 
assigning the statistical power comparison using a population approach. 
A relationship between age and changes in CsA pharmacokinetics was not 
found to be significant, possibly due to the patient population belonging to a 
limited age category (range 19-66). Burckart et al (35) did show an increase in 
clearance in pediatric liver transplant (1-5 years) showing that clearance of 
CsA may be several times higher in infants and up to twice as high in children 
than adults, however no study has shown the influence of adult age as a 
significant covariate on clearance. 
There are no reports in literature to support type of transplant affects CsA 
pharmacokinetics, and this study found no relationship between type of 
transplant and CUF. There has been a mixed response in order to ascertain the 
influence of weight on the pharmacokinetics of CsA. Certain authors (36) 
found weight not to influence the pharmacokinetics of cyclosporine, but others 
have found weight to be a significant covariate when modeled on CUF and 
V/F(20). In this study weight did have a significant change in objective 
function for CUF, however the CI of the estimates for weight involved a null 
value and hence was not considered significant and was not used for final 
model building. Weight was not identified as a significant covariate on V/F. It 
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is possible that the low number of patients and the limited weight range (39.6-
88 kg) made it difficult to adequately assess the significance of this covariate. 
In conclusion the population pharmacokinetics of cyclosporine in heart and 
lung transplant recipients was studied. Several patient characteristics such as 
concomitant itraconazole, presence of cystic fibrosis, different formulation of 
cyclosporine, and time post transplant were found to influence the 
pharmacokinetics of cyclosporine. It was found that during the first 4 weeks 
post transplant oral clearance decreased probably because absorption increased 
over 4 weeks time, concomitant itraconazole decreased oral clearance by 
43.9%, patients with CF has oral clearance higher by 50% than non-CF 
patients, and the bioavailability of Sandimmune was 87% that of Neoral. The 
presence of one or all of these covariates has been found to change the 
pharmacokinetics of cyclosporine and hence care should be taken when 
selecting a dosing regimen for patients with these characteristics. 
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( Table 2.1. Demographic Characteristic of the Patient Population 
Characteristics of the Population 
N=48 
Mean Age (years) 42 (range 19-66) 
Mean Total Body Weight 58.7 (range 39.6-88.0) 
(Kg) 
Gender 
Male N=26 
Female N=22 
Total Samples 1004 
Samples per patient t 21 (3-24) 
Formulation 
Sandimmune 21 
Neoral 27 
Cystic Fibrosis 8 
Concomitant ltraconazole 11 
Cystic Fibrosis and 
Concomitant ltraconazole 3 
Transplant Type 
Single Lung 18 
Double Lung 9 
Heart and Lung 21 
t 3 blood samples were obtained during a dosing interval at 0, 2 and 6 hours 
after dose. This was repeated for a maximum of 8 times over the course of a 
year. 
:j: Non-cystic fibrosis patients received cyclosporine (25-450mg) every 12-hour 
Cystic fibrosis patients received cyclosporine (100-500mg) every 8-hour. 
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Table 2.2. Summary of Analysis of Covariate Effect Tested on CUF 
Covariates Model OBJ i'.lOBJ % CV Significant 
(P=0.05) 
Base TVCL= 8 (1) -456.97 N.A 32.1 N.A. 
ltraconazole TVCL=81 + 85*1tra -1013.81 556.84 31 Significant 
Cystic Fibrosis TVCL=81+85*CF -739.75 282.02 23.7 Significant 
Formulation Fl=l *FORM+85*(1- -517.67 60.70 30.0 Significant 
FORM) 
Gender TVCL=81+85*SEX -617.85 160.88 33.2 Significant 
Time Post Fl= 1- 85 I TPT -680.30 223 .33 30.0 Signjficant 
Transplant 
WeightT TVCL=81+ 85*WT -549.22 92.24 32.1 Significant 
Age TVCL=81+85*Age -456.97 0 32.1 Not 
Significant 
Type of TVCL=81 +85*TYPE -457.35 0 32.1 Not 
Transplant Significant 
t Not included in the Final Model since estimate involved a null value in 95% CI 
Itra = ltraconazole. Patients on Itraconazole= 1, patients without itraconazole = 0 
CF= Cystic Fibrosis. Patients with CF=l, patients without CF=O 
FORM= Formulation. Neoral=O, Sandimmune=l 
Male= 1, Female=O 
WT= Weight in kilograms 
TPT= Time post transplant converted in weeks 
58 
Table 2.3. Backward Elimination of Significant Covariates to Build the Final 
Model 
Full No Itra No CF No Form NoTPT No Sex Final Model 
MOF -1369.92 -1012.86 -1164.06 -1356.65 -1269.26 -1369.92 -1369.93 
81 CUF 26.4 20.6 26.2 24.2 29.1 26.4 26.4 
Uhr (±4.7) (±4.8) (±4.9) (±2.7) (±5.1) (±3.7) (±3.7) 
82 V/FL 182 198 176 168 201 183 183 (±38) (±52) (±40) (±24) (±44) (±37) (±37) 
ka83 0.250 0.250 0.250 0.250 0.250 0.250 0.250 Sand h-1 
ka84 1.35 1.35 1.35 1.35 1.35 1.35 1.35 Neo h-1 
85 Itra 14.8 NA 14.l 13.8 17.1 14.8 14.8 (±4.5) (±4.6) (±3.7) (±4.6) (±4.3) (±4.3) 
86CF 25.9 25.9 NA 23.2 31.1 25.8 25.9 (±8.2) (±11.8) (±6.1) (±10.2) (±6.9) (±6.9) 
87 Form 1.14 1.22 1.11 NA 1.18 1.14 1.14 (±0.179) (±0.22) (±0.187) (±0.227) (±0.179) (±0.179) 
88TPT 0.355 0.434 0.423 0.34 NA 0.355 0.355 (±0.106) (±0.118) (±0.073) (±0.09) (±0.106) (±0.106) 
89 Sex 7.6e-007 6.80 2.02 3.3e-011 5.3e-005 NA NI (±4.80))1( (±6.9))1( (±5.45))1( (±4.68))1( (±5.43))1( 
%CV 18.6% 19.2% 28.5% 21.6% 19.5% 18.5% 18.6% 
Residual 49.6% 56.1% 49.7% 48.9% 52.1% 49.6% 49.6% Error 
)!(denotes null value in the estimates; MOF= Minimum value of Objective function; 
Form= Formulation; Neo=Neoral; Sand= Sandimmune; TPT =Time post transplant; 
TVCL= THETA( 1 )-THET A(5)*ITRA+ THETA( 6)*CF 
CL= TVCL *EXP(ET A( 1)) 
TVV=THET A(2) 
V=TVV 
IF (TPT .LE.4) TVFl = 1 *DOSE+ THET A(7)*( 1-DOSE)-THET A(8)!fPT 
Fl= TVFl 
IF (TPT.GT.4) TVFl=l *DOSE+THETA(7)*(1-DOSE) 
Fl=TVFl 
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Table 2.4. Comparison of Estimates for Base and Final Model 
Base Model Final Model 
Parameter Parameter Interpatient Parameter Interpatient 
(units) Estimates (95 % Variability Estimates (95 % Variability CV 
Cl) CV% (95% Cl) Cl) % (95% CI) 
81CL/F1Jhr 23.1(19.8 - 26.4) 32.l (24.2 -38.3) 26.4 (22.7 - 30.l) 18.5 (13.6 - 23.4) 
82 (V/F) L 202 (159 - 245) NA 183(146-220) NA 
83 I 84 (ka) h-1 
Sandimmune 0.25 Fixed NA 0.25 Fixed NA 
Neoral 1.35 Fixed NA 1.35 Fixed NA 
85 Itra NA NA 14.8(10.5-19.l) NA 
86CF NA NA 25.9(19 - 32.8) NA 
87F NA NA 1.14 (0.96 - 1.32) NA 
88TPT NA NA 0.355 (0.248-0.462) NA 
Residual error 60. l (50.9 -68.2) NA 49.6 (45.6-53.2) NA 
CV 
Abbreviations: CL/F =clearance; V/F =volume of distribution; ka =absorption rate constant; 
ltra= ltraconazole; CF=Cystic Fibrosis; F=Bioavailability; NA= not applicable 
TVCL=THETA(l)-THET A(5)*1TRA+ THET A(6)*CF; CL= TV CL *EXP(ETA( I)) 
TVV=THET A(2); V= TVV 
K=ClJV 
IF (DOSE.EQ.l) TVKA=THETA(3) 
KA=TVKA 
IF (DOSE.EQ.O) TVKA=THETA(4) 
KA=TVKA 
S2=V 
IF (TPT.LE.4) TVF l=l *DOSE+ THET A(7)*(1-DOSE)-THET A(8)/TPT 
Fl=TVFl 
IF (TPT.GT.4) TVFl=l *DOSE+ THETA(7)*(1-DOSE) 
Fl=TVFl 
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Figure 2.1. Kernel Graph CLi/CLx Versus Weeks Post Transplant. 
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Figure 2.2 (a): Base Model Observed Versus Model-Predicted Concentration 
(mg/L) 
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Figure. 2.2 (b): Weighted Residual Versus Model - Predicted Concentration 
0 
10 
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Figure 2.3: Box Plot for Cystic Fibrosis as Covariate 
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Figure 2.4: Box Plot for Formulation as Covariate. 
Patients on Neoral =0 and patients on Sandimmune =1 
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Figure 2.5. Box Plot for ltraconazole as Covariate 
Patients on itraconazole are marked 1, and patients not on itraconazole as 0. 
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( Figure 2.6 (a). Final Model Observed Versus Model - Predicted Concentration 
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Figure 2.6 (b ). 
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APPENDIX A 
Figure 3.1. NONMEM Control File for Base Model 
$PROB RUN# (BASE RUN) 
$INPUT C ID TIME AMT DV WT SS Dl=II TAD DOSE AGE SEX ITRA CF 
TPT 
$DATA 200.CSV IGNORE=C 
$SUBROUTINES ADV AN2 TRANS2 
$PK 
TVCL=THETA (1) 
CL=TVCL*EXP (ETA (1)) 
TVV=THETA (2) 
V=TVV 
K=CUV 
IF (DOSE.EQ.l) TVKA=THETA (3) 
KA=TVKA 
IF (DOSE.EQ.O) TVKA=THETA (4) 
KA=TVKA 
S2=V 
$ERROR 
Y=F*(l+ERR (1)) 
$THETA 
(0,105,500) (1,1000,5000) (0.25 FIXED) (1.35 FIXED) 
$OMEGA 
0.5; [P] INTERIND VAR IN CL 
$SIGMA 
0.3; [P] PROPORTIONAL COMPONENT 
$EST MAXEY AL=5000 PRINT=5 POSTHOC MSF=Base.MSF 
$COVARIANCE 
$TABLE ID TIME DOSE TAD IPRED CL V NOPRINT ONEHEADER 
FILE=Base.T AB 
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Figure 3.2. NONMEM Control File for Time Post Transplant 
$PROB RUN# TPT COY 
$INPUT C ID TIME AMT DV WT SS DI=II TAD DOSE AGE SEX ITRA CF 
TPT 
$DATA 200.CSV IGNORE=C 
$SUBROUTINES ADV AN2 TRANS2 
$PK 
TVCL=THETA (1) 
CL=TVCL*EXP (ETA (1)) 
TVV=THETA (2) 
V=TVV 
K=CUV 
IF (DOSE.EQ.1) TVKA=THETA (3) 
KA=TVKA 
IF (DOSE.EQ.O) TVKA=THETA (4) 
KA=TVKA 
S2=V 
IF (TPT.LE.4) TVFl=l-THETA (5)/TPT 
Fl=TVFl 
IF (TPT.GT.4) TVFl=l 
Fl=TVFl 
$ERROR 
Y=F*(l+ERR (1)) 
$THETA 
(0,105,500) (1, 1000, 5000) (0.25 FIXED) (1.35 FIXED) (0,0.007,0.6) 
$OMEGA 
0.5; [P] INTERIND VAR IN CL 
$SIGMA 
0.3; [P] PROPORTIONAL COMPONENT 
$EST MAXEY AL=5000 PRINT=5 POSTHOC 
$COY ARIAN CE 
$TABLE ID TIME DOSE TAD IPRED CL TPT NO PRINT ONEHEADER 
FILE=TPT.T AB 
75 
( Figure 3.3. NONMEM Control File for Itraconazole as Covariate 
$PROB RUN# ltra cov 
$INPUT C ID TIME AMT DV WT SS DI=II TAD DOSE AGE SEX ITRA CF 
TPT 
$DATA 200.CSV IGNORE=C 
$SUBROUTINES ADV AN2 TRANS2 
$PK 
TVCL=THETA (1)-THETA (5)*ITRA 
CL= TV CL *EXP (ETA (1)) 
TVV=THETA (2) 
V=TVV 
K=CUV 
IF (DOSE.EQ.l) TVKA=THETA (3) 
KA=TVKA 
IF (DOSE.EQ.O) TVKA=THETA (4) 
KA=TVKA 
S2=V 
$ERROR 
Y=F*(l+ERR (1)) 
$THETA 
(0,105,500) (1, 1000, 5000) (0.25 FIXED) (1.35 FIXED) (0, 10, 25) 
$OMEGA 
0.5; [P] INTERIND VAR IN CL 
$SIGMA 
0.3; [P] PROPORTIONAL COMPONENT 
$EST MAXEY AL=5000 PRINT=5 POSTHOC 
$COVARIANCE 
$TABLE ID TIME DOSE TAD IPRED CL ITRA NOPRINT ONEHEADER 
FILE=ltra.T AB 
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( Figure 3.4. NONMEM Control File for Formulation as Covariate. 
$PROB RUN# FORMULATION 
$INPUT C ID TIME AMT DV WT SS DI=II TAD DOSE AGE SEX ITRA CF 
TPT 
$DATA 200.CSV IGNORE=C 
$SUBROUTINES ADV AN2 TRANS2 
$PK 
TVCL=THETA (1) 
CL=TVCL*EXP (ETA (1)) 
TVV=THETA (2) 
V=TVV 
K=CUV 
IF (DOSE.EQ.l) TVKA=THETA (3) 
KA=TVKA 
IF (DOSE.EQ.0) TVKA=THETA (4) 
KA=TVKA 
S2=V 
Fl=l*DOSE+THETA (5)*(1-DOSE) 
$ERROR 
Y=F*(l+ERR (1)) 
$THETA 
(0,105,500) (1, 1000, 5000) (0.25 FIXED) (1.35 FIXED)(0,1,5) 
$OMEGA 
0.5; [P] INTERIND VAR IN CL 
$SIGMA 
0.3; [P] PROPORTIONAL COMPONENT 
$EST MAXEY AL=5000 PRINT=5 POSTHOC 
$COVARIANCE 
$TABLE ID TIME DOSE TAD IPRED CL NOPRINT ONEHEADER 
FILE=formulation.T AB 
77 
Figure 3.5. NONMEM Control File for Cystic Fibrosis as Covariate 
$PROB RUN# CF COV 
$INPUT C ID TIME AMT DV WT SS DI=II TAD DOSE AGE SEX ITRA CF 
TPT 
$DATA 200.CSV IGNORE=C 
$SUBROUTINES ADV AN2 TRANS2 
$PK 
TVCL=THETA (1) +THETA (5)*CF 
CL=TVCL*EXP (ETA (1)) 
TVV=THETA (2) 
V=TVV 
K=CUV 
IF (DOSE.EQ.1) TVKA=THETA (3) 
KA=TVKA 
IF (DOSE.EQ.O) TVKA=THETA (4) 
KA=TVKA 
S2=V 
$ERROR 
Y=F*(l+ERR (1)) 
$THETA 
(0,105,500) (1, 1000, 5000) (0.25 FIXED) (1.35 FIXED) (0, 35) 
$OMEGA 
0.5; [P] INTERIND VAR IN CL 
$SIGMA 
0.3; [P] PROPORTIONAL COMPONENT 
$EST MAXEY AL=5000 PRINT=5 POSTHOC 
$COVARIANCE 
$TABLE ID TIME TAD IPRED DOSE CL CF NOPRINT ONEHEADER 
FILE=CF.T AB 
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( Figure 3.6. NONMEM Control File for Final Model 
$PROB RUN# Final Model 
$INPUT C ID TIME AMT DV WT SS DI=II TAD DOSE AGE SEX ITRA CF 
TPT 
$DATA 200.CSV IGNORE=C 
$SUBROUTINES ADV AN2 TRANS2 
$PK 
TVCL=THETA (1)-THETA (5)*1TRA+THETA (6)*CF 
CL=TVCL*EXP (ETA (1)) 
TVV=THETA (2) 
V=TVV 
K=CUV 
IF (DOSE.EQ.l) TVKA=THETA (3) 
KA=TVKA 
IF (DOSE.EQ.O) TVKA=THETA (4) 
KA=TVKA 
S2=V 
IF (TPT.LE.4) TVFl=l *DOSE+ THETA (7)*(1-DOSE)-THETA (8)trPT 
Fl=TVFl 
IF (TPT.GT.4) TVFl=l *DOSE+ THETA (7)*(1-DOSE) 
Fl=TVFl 
$ERROR 
Y=F*(l+ERR (1)) 
$THETA 
(0,105,500) (1,1000,5000)(0.25 FIXED) (1.35 FIXED)(O,O.l,20)(0,5,35)(0.5,2,5) 
(0, 0.007' 0.6) 
$OMEGA 
0.5; [P] INTERIND VAR IN CL 
$SIGMA 
0.3; [P] PROPORTIONAL COMPONENT 
$EST MAXEY AL=5000 PRINT=5 POSTHOC 
$COVARIANCE 
$TABLE ID TIME DOSE TAD CL ITRA CF TPT NOPRINT ONEHEADER 
FILE=Final. TAB 
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( Figure 4.1. Results From the Analysis 
a. Base Model 
MINIMUM VALUE OF OBJECTIVE FUNCTION: -456.975 
FINAL 
ESTIMATE 
THETA 
1 23.1 
2 202 
3 0.250 
4 1.35 
OMEGA 
1,1 0.103 
SIGMA 
1,1 0.361 
95% CONFIDENCE INTERVAL 
%RSE LBOUND UBOUND 
7.27% 19.8 26.4 
10.7% 159 245 
INTERINDIVIDUAL 
VARIABILITY 
21.9% 0.0587 0.147 CV= 32.1% 
RESIDUAL 
VARIABILITY 
14.8% 0.256 0.466 CV= 60.1% 
%RSE is percent relative standard error (100% x SE/EST) 
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( b. Cystic Fibrosis 
MINIMUM VALUE OF OBJECTIVE FUNCTION: -739.749 
95% CONFIDENCE INTERVAL 
FINAL 
ESTIMATE %RSE LBOUND UBOUND 
THETA 
1 21.7 7.28% 18.6 24.8 
2 205 10.6% 162 248 
3 0.250 
4 1.35 
5 32.7 21.3% 19.0 46.4 
OMEGA INTERINDIVIDUAL 
VARIABILITY 
1,1 0.0563 25.8% 0.0279 0.0847 CV= 23.7% 
RESIDUAL 
SIGMA VARIABILITY 
1,1 0.367 13.7% 0.269 0.465 CV= 60.6% 
%RSE is percent relative standard error (100% x SE/EST) 
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( c. ltraconazale 
MINIMUM VALUE OF OBJECTNE FUNCTION: -1013.817 
FINAL 
ESTIMATE 
THETA 
1 28.0 
2 182 
3 0.250 
4 1.35 
5 16.3 
OMEGA 
1,1 0.0959 
SIGMA 
1,1 0.267 
95% CONFIDENCE INTERVAL 
%RSE LBOUND UBOUND 
6.61% 24.4 31.6 
6.98% 157 207 
13.7% 11.9 20.7 
INTERINDIVIDUAL 
VARIABILITY 
20.4% 0.0575 0.134 CV= 31.0% 
RESIDUAL 
VARIABILITY 
8.20% 0.224 0.310 CV= 51.7% 
%RSE is percent relative standard error (100% x SE/EST) 
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( d. Gender 
MINIMUM VALUE OF OBJECTIVE FUNCTION: -617 .857 
95% CONFIDENCE INTERVAL 
FINAL 
ESTIMATE %RSE LBOUND UBOUND 
THETA 
1 18.3 14.5% 13.1 23.5 
2 188 9.10% 154 222 
3 0.250 
4 1.35 
5 10.3 38.8% 2.46 18.1 
INTERINDIVIDUAL 
OMEGA VARIABILITY 
1,1 0.110 22.7% 0.0610 0.159 CV= 33.2% 
RESIDUAL 
SIGMA VARIABILITY 
1,1 0.319 11.4% 0.248 0.390 CV= 56.5% 
%RSE is percent relative standard error (100% x SE/EST) 
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( e. Formulation 
MINIMUM VALUE OF OBJECTIVE FUNCTION: -517 .676 
95% CONFIDENCE INTERVAL 
FINAL 
ESTIMATE %RSE LBOUND UBOUND 
THETA 
1 29.4 9.56% 23.9 34.9 
2 246 18.2% 158 334 
3 0.250 
4 1.35 
5 1.39 16.6% 0.937 1.84 
INTERINDIVIDUAL 
OMEGA VARIABILITY 
1,1 0.0897 22.3% 0.0505 0.129 CV= 29.9% 
RESIDUAL 
SIGMA VARIABILITY 
1,1 0.389 13.9% 0.283 0.495 CV= 62.4% 
%RSE is percent relative standard error (100% x SE/EST) 
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( f. Time Post Transplant 
MINIMUM VALUE OF OBJECTIVE FUNCTION: -680.309 
95% CONFIDENCE INTERVAL 
FINAL 
ESTIMATE %RSE LBOUND UBOUND 
THETA 
1 20.6 7.52% 17.6 23.6 
2 173 9.31% 141 205 
3 0.250 
4 1.35 
5 0.509 7.58% 0.433 0.585 
INTERINDIVIDUAL 
OMEGA VARIABILITY 
1,1 0.0901 20.0% 0.0548 0.125 CV= 30.0% 
RESIDUAL 
SIGMA VARIABILITY 
1,1 0.308 14.0% 0.224 0.392 CV= 55.5% 
%RSE is percent relative standard error (100% x SE/EST) 
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g. Final Model 
MINIMUM VALUE OF OBJECTIVE FUNCTION: -1369.928 
95% CONFIDENCE INTERVAL 
FINAL 
ESTIMATE %RSE LBOUND UBOUND 
THETA 
1 26.4 7.08% 22.7 30.1 
2 183 10.4% 146 220 
3 0.250 
4 1.35 
5 14.8 14.7% 10.5 19.1 
6 25.9 13.5% 19.0 32.8 
7 1.14 8.04% 0.960 1.32 
8 0.355 15.3% 0.248 0.462 
INTERINDIVIDUAL 
OMEGA VARIABILITY 
1,1 0.0344 28.9% 0.0149 0.0539 CV= 18.5% 
RESIDUAL 
SIGMA VARIABILITY 
1,1 0.246 7.93% 0.208 0.284 CV= 49.6% 
%RSE is percent relative standard error (100% x SE/EST) 
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